LONDON, UK and VALENCIA, Spain – June 2, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search for Quibim and is pleased to announce the placement of Itta MacNevin as Chief Business Officer (CBO). Quibim is a global pioneer in imaging biomarkers for precision medicine. The Company’s AI-powered, imaging-based solutions enable pharmaceutical companies to predict which patients will respond to a drug, identify suitable candidates for clinical trials, stratify patients by risk, and…
• Drug Discovery 2026 returns to ExCeL London from 14–15 October to celebrate 20 years of collaboration and inclusion
• Keynote programme includes presentation from Dr Sam Barrell CBE and panel discussion with Dr Anne Phelan, Dr Jason Mellad, Prof Sir Mene Pangalos and Prof Raghib Ali OBE
• Key topics include next-generation biophysics, microbes to medicines, multiomics, AI in compound discovery and experimental design, and bioconjugation approaches in oncology
Cambridge, UK, 01 June 2026: ELRIG, a not-for-profit, volunteer-led organisation dedicated to the global drug discovery community,…
Phase I study of an AI-designed oral formulation sets a new standard in drug developmentNOTTINGHAM, UK – 28 MAY 2026: Quotient Sciences today announces the successful initiation of a clinical study evaluating a novel drug product developed using artificial intelligence (AI) - a landmark achievement highlighting the growing potential of AI to guide formulation design and accelerate drug development. The pioneering Phase I clinical study was initiated at Quotient Sciences’ UK facility following approval from the Medicines and Healthcare products Regulatory Agency (MHRA). The study will…
1 June 2026
Researching the pros and cons of Annual Award Dinners and Company Showcase Pitching at conferences, respecting that the role of a not-for-profit membership organisation is to maximise support whilst mitigating any incurred overhead on its members, One Nucleus has transformed their approach to two of their flagship annual events. The Annual Awards will now form a key element within Genesis on Thursday 10 December in London.
There are three distinct advantages for our network:
Enabling greater connectivity and visibility to complement the profile and branding advantages of award-…
Source Cambridge Clinical Laboratories (Source CCL), part of Source BioScience UK Ltd, is strengthening its preventative health and oncology diagnostics offering through its established hereditary cancer testing services, supporting earlier risk identification and more informed clinical decision-making across the patient pathway.
Hereditary cancer testing plays a critical role in modern healthcare, enabling the identification of inherited cancer risk and supporting both individual patient management and broader population health strategies. As demand for earlier intervention and preventative…
Amsbio has launched a new range of authenticated cell lines covering a wide range of tumours, tissues, and species. With this addition of greater than 1000 independently verified human and animal cell lines, versatile primary and stem cells, the expanded range of top quality, cell lines from Amsbio are second to none.
The company is committed to providing cells that retain their original genetic composition and phenotypic characteristics, ensuring greater reliability and accuracy can be achieved in experimental results. Detailed documentation of every cell passage underscores the company…
Burlingame CA – 20 May 2026 – Download Press Release
Collaborative Drug Discovery (CDD), the leading provider of data management solutions for the pharmaceutical and biotechnology industries, today announced an agreement with Eli Lilly and Company (Lilly) to integrate Lilly TuneLab, a collaborative AI/ML drug discovery platform, into CDD Vault.
Lilly TuneLab was created by Lilly to accelerate biotech innovation by enabling participating companies to access models trained on decades of Lilly’s proprietary research data. Through this agreement, biotech companies that use CDD Vault will be able…
Welcome to the Q2 Edition of Our People Pathways Newsletter!
This issue is packed with practical opportunities to develop your skills and grow your network. You'll find upcoming training courses covering everything from communication to biological safety, plus a NEW seminar on maximising your cash runway - essential for anyone navigating life science funding. We're also spotlighting our next HR SIG session, mentoring initiative testimonials, and the latest toxicology course from CATS and BTS. And if you're passionate about supporting emerging talent, we have highlighted some student…
BURLINGAME, Calif., May 20, 2026 /PRNewswire/ -- Collaborative Drug Discovery (CDD), the leading provider of data management solutions for the pharmaceutical and biotechnology industries, today announced an agreement with Eli Lilly and Company (Lilly) to integrate Lilly TuneLab, a collaborative AI/ML drug discovery platform, into CDD Vault.
Lilly TuneLab was created by Lilly to accelerate biotech innovation by enabling participating companies to access models trained on decades of Lilly's proprietary research data. Through this agreement, biotech companies that use CDD Vault will be able to…
LONDON, UK, and COPENHAGEN, Denmark – May 14, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search for Neumirna Therapeutics (“Neumirna”) and is pleased to announce the placement of Dr. Ferenc Tracik as Chief Medical Officer (CMO). Neumirna Therapeutics is a biotechnology company dedicated to developing RNA-based therapies for complex neurological diseases. Dr. Tracik is a physician-leader with more than two decades of expertise in neurological and rare disease…